ASX:BOT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Botanix Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BOT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.0%

BOT

5.4%

AU Pharmaceuticals

2.4%

AU Market


1 Year Return

-59.1%

BOT

-12.0%

AU Pharmaceuticals

-15.0%

AU Market

Return vs Industry: BOT underperformed the Australian Pharmaceuticals industry which returned -12% over the past year.

Return vs Market: BOT underperformed the Australian Market which returned -15% over the past year.


Shareholder returns

BOTIndustryMarket
7 Day7.0%5.4%2.4%
30 Day-16.4%13.0%6.5%
90 Day-46.5%-4.0%-20.8%
1 Year-59.1%-59.1%-11.8%-12.0%-11.5%-15.0%
3 Year4.5%4.5%-25.9%-26.6%7.3%-6.9%
5 Yearn/a-30.7%-34.3%18.0%-7.5%

Price Volatility Vs. Market

How volatile is Botanix Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Botanix Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BOT (A$0.05) is trading below our estimate of fair value (A$2.37)

Significantly Below Fair Value: BOT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BOT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: BOT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BOT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BOT is good value based on its PB Ratio (1.4x) compared to the AU Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is Botanix Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

95.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: BOT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BOT's is expected to become profitable in the next 3 years.

Revenue vs Market: BOT's revenue (85.8% per year) is forecast to grow faster than the Australian market (4.3% per year).

High Growth Revenue: BOT's revenue (85.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOT is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Botanix Pharmaceuticals performed over the past 5 years?

-53.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BOT is currently unprofitable.

Growing Profit Margin: BOT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BOT is unprofitable, and losses have increased over the past 5 years at a rate of -53.2% per year.

Accelerating Growth: Unable to compare BOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).


Return on Equity

High ROE: BOT has a negative Return on Equity (-59.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Botanix Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BOT's short term assets (A$35.0M) exceed its short term liabilities (A$2.0M).

Long Term Liabilities: BOT's short term assets (A$35.0M) exceed its long term liabilities (A$348.2K).


Debt to Equity History and Analysis

Debt Level: BOT is debt free.

Reducing Debt: BOT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BOT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BOT has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 56.3% each year.


Next Steps

Dividend

What is Botanix Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BOT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BOT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Vince Ippolito (60yo)

1.33yrs

Tenure

AU$545,049

Compensation

Mr. Vincent P. Ippolito, also known as Vince, serves as the President of Botanix Pharmaceuticals Limited since May 20, 2019 and Executive Chairman since July 18, 2019. Mr. Ippolito is Acting Managing Direc ...


CEO Compensation Analysis

Compensation vs Market: Vince's total compensation ($USD355.71K) is above average for companies of similar size in the Australian market ($USD250.60K).

Compensation vs Earnings: Insufficient data to compare Vince's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Vincent Ippolito
MD, President & Executive Chairman1.33yrsAU$545.05kno data
Michael Thurn
COO & Executive Director1.25yrsAU$1.06m0.26% A$114.6k
Henry Bosch
Chief Scientific Officer & Executive Director3.83yrsAU$180.03k1.64% A$720.0k
Matthew Callahan
Executive Director0.25yrAU$281.12k7.27% A$3.2m
Simon Robertson
Company Secretary3.25yrsno datano data

2.3yrs

Average Tenure

Experienced Management: BOT's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vincent Ippolito
MD, President & Executive Chairman1.33yrsAU$545.05kno data
Michael Thurn
COO & Executive Director1.25yrsAU$1.06m0.26% A$114.6k
Henry Bosch
Chief Scientific Officer & Executive Director3.83yrsAU$180.03k1.64% A$720.0k
Matthew Callahan
Executive Director0.25yrAU$281.12k7.27% A$3.2m
Stewart Washer
Non-Executive Director1.25yrsAU$90.34kno data

1.3yrs

Average Tenure

49yo

Average Age

Experienced Board: BOT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.1%.


Top Shareholders

Company Information

Botanix Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Botanix Pharmaceuticals Limited
  • Ticker: BOT
  • Exchange: ASX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$43.771m
  • Shares outstanding: 972.70m
  • Website: https://www.botanixpharma.com

Number of Employees


Location

  • Botanix Pharmaceuticals Limited
  • 50 Angove Street
  • Level 1
  • North Perth
  • Western Australia
  • 6006
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJul 2016
BOTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJul 2016
BXPH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2016

Biography

Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; BTX 1701, a novel product for mild acne; and BTX 1801, a novel antimicrobial. The company is based in North Perth, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 10:58
End of Day Share Price2020/05/25 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.